EvoGenix Limited

EvoGenix was an Australian biopharmaceutical company specializing in the development and optimization of monoclonal antibodies and related protein therapeutics using proprietary platforms such as Superhumanisation™, EvoGene™ Optimisation, and Evibodies™ technology. The company's focus areas included inflammatory diseases like rheumatoid arthritis, osteoporosis/bone loss disorders, oncology indications including lung cancer/melanoma via both direct mAbs and innovative peptide-antibody conjugates from its US subsidiary Absalus Inc., as well as respiratory infections. It operated through both internal product development—primarily preclinical—and strategic collaborations with major pharmaceutical companies including GlaxoSmithKline and CSL. In mid–2007 it was acquired by Peptech Limited to form a leading international player in the field of therapeutic antibodies before being subsumed into Arana Therapeutics following further industry consolidation.